AR070255A1 - Derivados de urea de tetrahidroquinoxalina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la modulacion de la actividad de 11-beta hd1 (hidroxiesteroide deshidrogenasa de tipo 1) - Google Patents
Derivados de urea de tetrahidroquinoxalina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la modulacion de la actividad de 11-beta hd1 (hidroxiesteroide deshidrogenasa de tipo 1)Info
- Publication number
- AR070255A1 AR070255A1 ARP090100229A ARP090100229A AR070255A1 AR 070255 A1 AR070255 A1 AR 070255A1 AR P090100229 A ARP090100229 A AR P090100229A AR P090100229 A ARP090100229 A AR P090100229A AR 070255 A1 AR070255 A1 AR 070255A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- coor5
- nr6r7
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Compuesto que responde a la formula (1) en la que A representa un enlace, un átomo de oxigeno o un grupo -O-CH2-, Ar1 representa un grupo fenilo o heteroarilo, Ar2 representa un grupo fenilo, un grupo heteroarilo o un grupo heterocicloalquilo, R1a, b, c y R2a, b, c, idénticos, o diferentes, representan cada uno un átomo de hidrogeno o de halogeno o un grupo alquilo, cicloalquilo, -alquil-cicloalquilo sustituido opcionalmente con uno o varios átomos de halogeno, -OR5 (hidroxi o alcoxi), hidroxialquilo, alcoxi-alquilo, alcoxi-alcoxi, halogenoalquilo, -O-halogenoalquilo, oxo, -CO-alquilo, -CO-alquilo-NR6R7, -CO-halogenoalquilo, -COOR5, alquil-COOR5, -O-alquil-COOR5, -SO2-alquilo, -SO2-cicIoalquilo, -SO2-alquil-cicloalquilo, -SO2-alquilo-OR5, -SO2-aIquil-COOR5, -SO2-alquil-NR6R7, -SO2-halogenoalquilo, alquil-SO2-alquilo, -SO2-NR6R7, -SO2-alquil-alcoxi-alcoxi, -CONR6R7, -alquil-CONR6R7 o -O-alquil-NR6R7, o R1a, R1b, R1c están unidos respectivamente a R2a, R2b, R2c y al átomo de carbono al que están unidos y representan -O-alquil-O-; R3 representa un átomo de hidrogeno o un grupo alquilo, R4 representa un átomo de hidrogeno o de halogeno o un grupo ciano, -OR5, hidroxi-alquilo, -COOR5, -NR6R7, -CONR6R7, -SO2-alquilo o -SO2-NR6R7, -NR6-COOR5, -NR6-COR5, -CO-NR6-alquil-OR5; R5, R6 y R7, idénticos o diferentes, representan cada uno un átomo de hidrogeno, un grupo alquilo o un grupo -alquil-fenilo, y R8 representa un átomo de hidrogeno, un grupo alquilo o un grupo de formula -B-Het, en la que B puede estar ausente o representar un enlace, un átomo de oxígeno o un grupo -CO- o -SO2-(CH2)n con n igual a 0, 1 o 2 y en la que Het representa un heteroarilo o un heterocicloalquilo sustituido opcionalmente con 1 a 3 grupos elegidos entre los grupos alquilos, -SO2-alquilos y -COOR5, en el estado de base o de ácido o de sal de adicion a un ácido o a una base. Reivindicacion 21: Compuestos de formulas (2) y (4) en las que A, Ar1, Ar2, R1a, b, c, R2a, b, c y R8 son tales como se han definido en una cualquiera de las reivindicaciones 1 a 6 y 9 a 12 y Lg representa un grupo saliente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800429A FR2926817B1 (fr) | 2008-01-28 | 2008-01-28 | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
| FR0804521A FR2934858B1 (fr) | 2008-08-08 | 2008-08-08 | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070255A1 true AR070255A1 (es) | 2010-03-25 |
Family
ID=41037885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100229A AR070255A1 (es) | 2008-01-28 | 2009-01-26 | Derivados de urea de tetrahidroquinoxalina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la modulacion de la actividad de 11-beta hd1 (hidroxiesteroide deshidrogenasa de tipo 1) |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8211892B2 (es) |
| EP (1) | EP2238126B1 (es) |
| JP (1) | JP2011510919A (es) |
| KR (1) | KR20100111308A (es) |
| CN (1) | CN101981026A (es) |
| AR (1) | AR070255A1 (es) |
| AU (1) | AU2009224546B2 (es) |
| BR (1) | BRPI0906567A2 (es) |
| CA (1) | CA2713367A1 (es) |
| CL (1) | CL2009000173A1 (es) |
| CO (1) | CO6290672A2 (es) |
| CR (1) | CR11596A (es) |
| DO (1) | DOP2010000230A (es) |
| EA (1) | EA201070895A1 (es) |
| EC (1) | ECSP10010368A (es) |
| IL (1) | IL207195A (es) |
| MA (1) | MA32098B1 (es) |
| MX (1) | MX2010008290A (es) |
| NI (1) | NI201000130A (es) |
| PA (1) | PA8813701A1 (es) |
| PE (1) | PE20091323A1 (es) |
| TW (1) | TW200936136A (es) |
| UY (1) | UY31616A1 (es) |
| WO (1) | WO2009112691A2 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| NZ619413A (en) | 2006-05-04 | 2015-08-28 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
| TW200936136A (en) * | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| FR2948369B1 (fr) * | 2009-07-27 | 2013-04-12 | Sanofi Aventis | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
| FR2948370B1 (fr) * | 2009-07-27 | 2013-04-05 | Sanofi Aventis | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
| JP5753790B2 (ja) | 2009-11-11 | 2015-07-22 | 大日本住友製薬株式会社 | ８−アザビシクロ［３．２．１］オクタン−８−カルボキサミド誘導体 |
| JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療 |
| US8796468B2 (en) | 2009-12-22 | 2014-08-05 | Shionogi & Co., Ltd. | Adamantanamine derivative |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| EP2604591A4 (en) | 2010-08-09 | 2015-07-22 | Shionogi & Co | PROCESS FOR THE PREPARATION OF AMINOADAMANTYL CARBAMATE DERIVATIVES |
| WO2012029942A1 (ja) | 2010-09-03 | 2012-03-08 | 大日本住友製薬株式会社 | 環状アミド誘導体 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| CN103781788B (zh) | 2011-07-15 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 经取代的喹唑啉、其制备及其在药物组合物中的用途 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20150087628A1 (en) * | 2012-04-10 | 2015-03-26 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| JP6043767B2 (ja) * | 2014-09-26 | 2016-12-14 | 株式会社アステム | 番組出力装置、補助情報管理サーバ、番組と補助情報の出力方法、及びプログラム |
| MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
| KR102177304B1 (ko) | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| CN109956958B (zh) * | 2019-04-02 | 2020-06-16 | 河北合佳医药科技集团股份有限公司 | 一种7-氨基-3-甲氧基甲基-3-头孢烯-4-羧酸合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| GB0505541D0 (en) * | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
| TW200811170A (en) * | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Urea derivatives of tropane, their preparation and their therapeutic application |
| TW200811158A (en) * | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application |
| US8222417B2 (en) * | 2007-06-27 | 2012-07-17 | Taisho Pharmaceutical Co., Ltd | Compound having 11β-HSD1 inhibitory activity |
| WO2009020140A1 (ja) * | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | アダマンチルウレア誘導体 |
| TW200936136A (en) * | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
-
2009
- 2009-01-23 TW TW098103125A patent/TW200936136A/zh unknown
- 2009-01-26 AR ARP090100229A patent/AR070255A1/es not_active Application Discontinuation
- 2009-01-26 PE PE2009000105A patent/PE20091323A1/es not_active Application Discontinuation
- 2009-01-27 CA CA2713367A patent/CA2713367A1/fr not_active Abandoned
- 2009-01-27 PA PA20098813701A patent/PA8813701A1/es unknown
- 2009-01-27 MX MX2010008290A patent/MX2010008290A/es active IP Right Grant
- 2009-01-27 CN CN2009801113945A patent/CN101981026A/zh active Pending
- 2009-01-27 AU AU2009224546A patent/AU2009224546B2/en not_active Ceased
- 2009-01-27 BR BRPI0906567-9A patent/BRPI0906567A2/pt not_active IP Right Cessation
- 2009-01-27 WO PCT/FR2009/000083 patent/WO2009112691A2/fr active Application Filing
- 2009-01-27 EP EP09720707.0A patent/EP2238126B1/fr active Active
- 2009-01-27 EA EA201070895A patent/EA201070895A1/ru unknown
- 2009-01-27 KR KR1020107019130A patent/KR20100111308A/ko active Search and Examination
- 2009-01-27 JP JP2010543545A patent/JP2011510919A/ja active Pending
- 2009-01-28 UY UY031616A patent/UY31616A1/es not_active Application Discontinuation
- 2009-01-28 CL CL2009000173A patent/CL2009000173A1/es unknown
-
2010
- 2010-07-23 EC EC2010010368A patent/ECSP10010368A/es unknown
- 2010-07-25 IL IL207195A patent/IL207195A/en not_active IP Right Cessation
- 2010-07-26 US US12/843,124 patent/US8211892B2/en not_active Expired - Fee Related
- 2010-07-26 NI NI201000130A patent/NI201000130A/es unknown
- 2010-07-27 CR CR11596A patent/CR11596A/es not_active Application Discontinuation
- 2010-07-27 DO DO2010000230A patent/DOP2010000230A/es unknown
- 2010-07-28 CO CO10092048A patent/CO6290672A2/es not_active Application Discontinuation
- 2010-08-23 MA MA33110A patent/MA32098B1/fr unknown
-
2012
- 2012-05-30 US US13/483,710 patent/US8530657B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2238126A2 (fr) | 2010-10-13 |
| TW200936136A (en) | 2009-09-01 |
| CA2713367A1 (fr) | 2009-09-17 |
| CN101981026A (zh) | 2011-02-23 |
| MX2010008290A (es) | 2010-08-18 |
| IL207195A (en) | 2013-12-31 |
| CR11596A (es) | 2010-09-13 |
| US8530657B2 (en) | 2013-09-10 |
| PA8813701A1 (es) | 2009-09-17 |
| NI201000130A (es) | 2010-12-17 |
| IL207195A0 (en) | 2010-12-30 |
| CO6290672A2 (es) | 2011-06-20 |
| CL2009000173A1 (es) | 2010-02-12 |
| DOP2010000230A (es) | 2010-08-31 |
| PE20091323A1 (es) | 2009-09-26 |
| BRPI0906567A2 (pt) | 2015-07-07 |
| WO2009112691A2 (fr) | 2009-09-17 |
| EP2238126B1 (fr) | 2014-11-05 |
| UY31616A1 (es) | 2009-08-31 |
| US20120245148A1 (en) | 2012-09-27 |
| ECSP10010368A (es) | 2010-08-31 |
| EA201070895A1 (ru) | 2011-04-29 |
| US20110009391A1 (en) | 2011-01-13 |
| US8211892B2 (en) | 2012-07-03 |
| AU2009224546B2 (en) | 2014-01-30 |
| KR20100111308A (ko) | 2010-10-14 |
| AU2009224546A1 (en) | 2009-09-17 |
| MA32098B1 (fr) | 2011-02-01 |
| WO2009112691A3 (fr) | 2010-01-07 |
| JP2011510919A (ja) | 2011-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070255A1 (es) | Derivados de urea de tetrahidroquinoxalina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la modulacion de la actividad de 11-beta hd1 (hidroxiesteroide deshidrogenasa de tipo 1) | |
| ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
| AR062074A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| CR20190244A (es) | Agentes control de plaga | |
| UY30874A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica. | |
| ECSP14013264A (es) | Nuevos derivados bicíclicos de dihidroquinolina-2-ona | |
| AR081331A1 (es) | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR077440A1 (es) | Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas | |
| GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
| AR061603A1 (es) | Derivados de etenilcarboxamidas microbicidas | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
| HN2005000370A (es) | Derivados de pirido-pirimidina, su preparacion y su aplicacion en terapeutica | |
| ECSP099216A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno | |
| AR081495A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |